Information Provided By:
Fly News Breaks for November 14, 2019
VBLT
Nov 14, 2019 | 14:49 EDT
Chardan analyst Geulah Livshits upgraded VBL Therapeutics to Buy from Neutral with a $3.25 price target, stating that she sees limited downside for the shares as the report of interim data for its OVAL Phase 3 potential-registration trial of VB-111 in ovarian cancer approaches.
News For VBLT From the Last 2 Days
There are no results for your query VBLT